查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1990206

卡納萬病治療市場：2026-2032年全球市場預測（按治療方法、給藥途徑、治療線、開發商、技術、患者年齡層和最終用戶分類）

Canavan Disease Therapeutics Market by Therapy Type, Route Of Administration, Therapy Line, Developer Type, Technology, Patient Age Group, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，卡納萬病治療市場價值將達到 5.9107 億美元，到 2026 年將成長至 6.2275 億美元，到 2032 年將達到 8.9437 億美元，複合年成長率為 6.09%。

主要市場統計數據
基準年 2025 591,070,000 美元
預計年份：2026年 6.2275億美元
預測年份 2032 8.9437億美元
複合年成長率 (%) 6.09%

重點在於影響卡納萬病下一代治療方法研發的臨床和科學需求及其策略背景。

卡納萬氏症是一種由Aspart缺乏引起的進行性性中樞神經系統海綿狀變性，至今仍是臨床上最具挑戰性的白質營養不良症之一。儘管數十年來在分子層面上對其進行了闡明，但由於難以穿過血腦障壁、缺乏自然病程的資料集以及特徵明確的患者隊列稀少等問題，治療方法的開發仍然受到限制。目前的進展反映了一個學習曲線。臨床前模型比以往更具預測性，載體技術、給藥方案和生物標記開發近年來也取得了顯著進展。

載體技術、精確編輯平台以及不斷發展的監管和生產模式如何重塑卡納萬病治療方法的發展。

隨著基因傳遞、精準編輯和輔助藥理學領域的創新融合，卡納萬病治療格局正在發生變革性變化。載體技術不斷發展，親和性並降低了免疫抗原性，從而實現了更可靠的全身和腦實質內給藥策略。同時，基因組編輯平台的進步使得永久性矯正方法的探索成為可能，而小分子調控作為一種旨在解決代謝異常和症狀的補充策略仍然至關重要。

評估 2025 年美國關稅調整將如何影響先進治療藥物的供應鏈動態、籌資策略和生產韌性。

美國於2025年實施的關稅調整對卡納萬病治療生態系統產生了多方面的影響，改變了關鍵原料的成本結構和物流。專用設備、一次性生物反應器組件和先進試劑的供應商面臨更高的進口關稅，導致接收成本上升和採購前置作業時間延長。由於基因治療項目依賴高度特異性的原料和跨境供應鏈，這些與關稅相關的摩擦導致生產宣傳活動的靈活性降低，並需要採取替代的籌資策略。

綜合細分分析，解釋治療方法、管理方法、分銷、最終用戶環境、開發商類型、技術和患者年齡如何影響策略決策。

精準理解細分市場對於解讀整個卡納萬病治療計畫中的治療機會和運作重點至關重要。按治療方法分類，該領域包括酵素替代療法、基因療法和小分子療法。在基因療法中，遞送方式主要分為腺相關病毒（AAV）載體和慢病毒載體平台；而小分子療法則可能專注於鋰或N-乙醯半胱胺酸等藥物。給藥途徑也是一個關鍵因素，包括肌肉注射、靜脈注射和口服。每種途徑對藥物動力學、患者依從性和臨床監測的影響各不相同。分銷管道，包括醫院藥房、線上藥房和零售藥房，構成了藥物可近性和依從性的途徑。所有這些都與報銷機制和患者支援服務緊密相連。

區域監管差異、生產能力分配和臨床網路成熟度如何影響全球市場的適應性開發和存取策略？

區域趨勢對卡納萬病治療的研發策略、與監管機構的合作以及患者用藥途徑都起著至關重要的作用。在美洲，臨床專業知識和先進製造能力的集群為早期臨床試驗和商業化計劃提供了強大的生態系統，同時，監管路徑也強調了已建立的罕見疾病快速核准框架。在歐洲、中東和非洲，法規環境各不相同，先進的臨床網路和報銷機製水平也存在差異，這要求申辦方根據區域情況調整證據材料和准入策略。在亞太地區，新興的臨床試驗能力、不斷發展的生物技術生態系統以及擴大本地製造的努力，為擴大規模和降低生產成本提供了極具吸引力的選擇，但監管協調仍然是一項持續的挑戰。

這項公司層面的競爭考察揭示了科學專長、合作策略和製造夥伴關係如何決定生態系統內的專案進度和合作。

在卡納萬病領域，各主要企業在科學研究重點、生產策略及合作模式方面各有特色。一些研發公司強調其載體工程和基因組編輯平台的深度，大力投資於臨床前檢驗和載體最佳化，以確保基因在中樞神經系統（CNS）中的持續表達和良好的安全性。另一些公司則優先考慮轉化應用的靈活性，透過結合現有藥物的再利用和輔助性治療，在基因工程計畫成熟的同時，減輕症狀負擔並延長治療療程。整體，高度專業化的生技研發公司與大型製藥企業之間的合作十分普遍，這種合作模式將深厚的科研專長與商業基礎設施和支付方的對接能力相結合。

為產業領導者提供切實可行的方法，以增強罕見疾病計畫的供應彈性、監管合規性、病人參與和生產規模化能力。

產業領導者應採取一系列切實可行的策略，以應對卡納萬病治療藥物複雜的研發和商業化路徑。首先，優先考慮供應鏈的韌性至關重要。透過認證多家供應商、投資於地域分散的生產能力以及製定穩健的關鍵原料庫存計劃，可以降低項目脆弱性。其次，儘早與監管機構就可接受的替代終點和適應性試驗設計達成一致，可以降低關鍵研發路徑上的風險，並提高研發進度的可預測性。第三，將患者權益倡導組織納入通訊協定和自然史研究的共同設計中，可以提高臨床實驗的相關性，加快受試者招募，並加強真實世界數據（REW）的收集。

採用透明的混合方法研究途徑，結合文獻整合、專家訪談和嚴格的檢驗，以檢驗策略結論和建議。

本研究採用混合方法，結合了全面的二手文獻整合、一手質性訪談和嚴格的交叉檢驗。同行評審的科學文獻、監管指導文件、會議論文集和技術白皮書被用作第二手資料，以建立科學和監管背景。一手研究包括對專攻腦白質營養不良的臨床醫生、病毒載體生產專家、監管事務專家、醫保報銷專家以及患者權益倡導組織負責人進行結構化訪談，以了解實踐經驗、優先排序標準和實際限制因素。

結論指出，營運韌性、策略合作和轉化一致性對於將科學進步轉化為患者影響至關重要。

開發治療卡納萬病的有效治療方法，關鍵在於技術創新、以患者為中心的臨床試驗設計以及切實可行的操作實施三者之間的交匯。載體設計、基因組編輯和輔助藥理學的科學進步，已開闢出多條前景廣闊的治療途徑，但其成功實用化需要仔細考慮生產規模、監管策略以及患者參與等因素。諸如關稅相關的採購困難等短期干擾，凸顯了建構具有韌性的供應鏈和區域性生產策略的必要性。同時，監管的柔軟性和臨床試驗設計的進步，為在不降低證據品質的前提下加速研發提供了契機。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：卡納萬病治療市場（依治療方法分類）

  • 酵素替代療法
  • 基因治療
    • AAV 載體
    • 慢病毒載體
  • 小分子療法
    • 鋰
    • N-乙醯半胱胺酸

第9章：卡納萬病治療市場：依給藥途徑分類

  • 肌肉內部
  • 靜脈
  • 口服

第10章：按治療系列分類的卡納萬病治療市場

  • 一線治療
  • 二級治療

第11章：按開發商類型分類的卡納萬病治療市場

  • 生技公司
  • 製藥公司

第12章：卡納萬病治療市場：依技術分類

  • CRISPR-Cas9
  • 天賦
  • ZFN

第13章：依病患年齡層別分類的卡納萬病治療市場

  • 成年患者
  • 兒童患者

第14章 卡納萬病治療市場：依最終用戶分類

  • 診所
  • 居家照護設施
  • 醫院

第15章：卡納萬病治療市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章 卡納萬病治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 卡納萬病治療市場：按國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章：美國卡納萬病治療市場

第19章：中國卡納萬病治療市場

第20章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abeona Therapeutics Inc.
  • Amgen, Inc.
  • Anjarium Biosciences AG
  • Astellas Pharma Inc.
  • Biogen Inc.
  • BridgeBio Pharma
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Myrtelle, Inc.
  • Novartis AG
  • Orchard Therapeutics PLC
  • Orphan Star Therapeutics LLC
  • Pfizer, Inc.
  • Sanofi SA
  • Sio Gene Therapies Inc.
  • Ultragenyx Pharmaceutical Inc.
  • Voyager Therapeutics, Inc.
Product Code: MRR-99555D550525

The Canavan Disease Therapeutics Market was valued at USD 591.07 million in 2025 and is projected to grow to USD 622.75 million in 2026, with a CAGR of 6.09%, reaching USD 894.37 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 591.07 million
Estimated Year [2026] USD 622.75 million
Forecast Year [2032] USD 894.37 million
CAGR (%) 6.09%

A focused orientation to the clinical and scientific imperatives shaping next-generation therapeutic development for Canavan disease with strategic context

Canavan disease remains one of the most clinically challenging leukodystrophies, characterized by progressive spongiform degeneration of the central nervous system driven by aspartoacylase deficiency. Despite decades of molecular characterization, therapeutic development has been constrained by blood-brain barrier delivery challenges, limited natural history datasets, and the rarity of well-characterized patient cohorts. The current development landscape reflects a learning curve: preclinical models are more predictive than before, and vectorology, dosing paradigms, and biomarker development have advanced materially over the last several years.

As clinical teams translate mechanistic insights into human studies, industry stakeholders must reconcile scientific potential with operational realities. Manufacturing capacity for viral vectors, standardization of outcome measures, and alignment with rare-disease regulatory pathways are immediate priorities. In parallel, patient advocacy groups and clinician networks are increasingly shaping trial design and recruitment strategies, enabling more patient-centric approaches. Taken together, these elements frame a high-stakes but increasingly navigable pathway from bench to bedside for Canavan disease therapeutics.

How advances in vector technology, precision editing platforms, and evolving regulatory and manufacturing paradigms are reshaping Canavan disease therapeutic development

The therapeutic landscape for Canavan disease is undergoing transformative shifts as innovations in gene delivery, precision editing, and supportive pharmacology converge. Vector technologies have evolved to offer improved central nervous system tropism and reduced immunogenicity, enabling more credible systemic and intraparenchymal delivery strategies. Concurrently, advances in genome editing platforms permit exploration of permanent corrective approaches, while small molecule modulation remains relevant as a complementary strategy to address metabolic dysregulation and symptomatic needs.

Regulatory and payer frameworks are also adapting to rare disease realities. Accelerated approval pathways, adaptive trial design options, and expanded access mechanisms are influencing developmental timelines and commercial planning. Meanwhile, manufacturing innovations-such as scalable vector production and modular cell-processing workflows-are de-risking supply constraints that historically impeded progress. These converging shifts are changing how sponsors prioritize programs, allocate capital, and engage with clinical networks, ultimately creating a more dynamic environment for translating promising science into viable therapies.

An assessment of how the 2025 United States tariff adjustments altered supply chain dynamics, procurement strategies, and manufacturing resilience for advanced therapeutics

United States tariff changes implemented in 2025 have exerted a multifaceted influence on the Canavan disease therapeutic ecosystem by altering the cost structure and logistics of sourcing critical inputs. Suppliers of specialized equipment, single-use bioreactor components, and advanced reagents faced elevated import duties that increased landed costs and extended procurement lead times. Because gene therapy programs rely on highly specific raw materials and cross-border supply chains, these tariff-driven frictions translated into tighter scheduling buffers for manufacturing campaigns and a need for alternative sourcing strategies.

In response, sponsors and contract development and manufacturing organizations have accelerated nearshoring initiatives and diversified supplier bases to mitigate supply chain concentration risk. This operational pivot has implications for program budgets and timeline management, as qualification of new suppliers and revalidation of processes require time and investment. At the same time, clinical operations teams have recalibrated inventory strategies for critical supplies to prevent trial disruptions. While tariffs introduced short-term headwinds, they also prompted a strategic reassessment of supply resilience and have catalyzed investments in domestic capacity expansion and procurement agility that could yield longer-term benefits for rare disease program continuity.

Integrated segmentation analysis explaining how therapy modality, delivery approach, distribution, end user settings, developer type, technology and patient age inform strategic decisions

A nuanced understanding of segmentation is essential to interpret therapeutic opportunity and operational priorities across Canavan disease programs. When therapies are categorized by treatment modality, the field includes enzyme replacement therapy, gene therapy, and small molecule therapy; within gene therapy, delivery approaches are differentiated by AAV vector and lentiviral vector platforms, while small molecule programs may focus on lithium or N-acetylcysteine as pharmacologic approaches. Route of administration is another critical axis, encompassing intramuscular, intravenous, and oral modalities, each with distinct implications for pharmacokinetics, patient adherence, and clinical monitoring. Distribution channels shape access and adherence pathways, spanning hospital pharmacies, online pharmacies, and retail pharmacies, all of which interact with reimbursement mechanisms and patient support services.

End user dynamics-clinics, homecare settings, and hospitals-inform both delivery feasibility and real-world evidence generation, while therapy line classification into first-line and second-line treatments determines clinical positioning and payer negotiation strategies. Developer type separates approaches by biotech companies and pharmaceutical companies, with differences in risk tolerance, vertical capabilities, and commercialization reach. Technology platforms such as CRISPR-Cas9, TALEN, and ZFN provide mechanistic differentiation that affects regulatory engagement and intellectual property strategies. Finally, patient age group stratification into adult and pediatric populations drives distinct clinical trial designs, outcome measures, and safety monitoring frameworks. Together, these segmentation dimensions create an interlocking framework that guides program design, clinical development priorities, and commercialization tactics.

How regional regulatory variability, manufacturing capacity allocation, and clinical network maturity influence adaptive development and access strategies across global markets

Regional dynamics have a determinative effect on development strategies, regulatory interactions, and patient access for Canavan disease therapeutics. In the Americas, concentrated centers of clinical expertise and advanced manufacturing capacity underpin a strong ecosystem for early-phase testing and commercialization planning, and regulatory pathways emphasize established rare disease mechanisms for expedited engagement. Europe, Middle East & Africa present heterogenous regulatory environments with pockets of advanced clinical networks and reimbursement variability, prompting sponsors to tailor evidence packages and access strategies region by region. In the Asia-Pacific region, emerging clinical trial capacity, growing biotech ecosystems, and efforts to expand local manufacturing create compelling options for scale and cost-efficient production, although regulatory harmonization remains a work in progress.

These regional distinctions affect everything from trial site selection and patient recruitment to supply chain routing and pricing strategy. As a result, cross-regional planning is now a core competency for sponsors, requiring harmonized data standards, pragmatic regulatory submission planning, and culturally competent patient engagement approaches. Strategic partnerships with regional clinical networks and contract manufacturers can accelerate program timelines while managing regulatory and commercial complexity across distinct geographies.

Competitive company-level insights revealing how scientific specialization, partnership strategies, and manufacturing partnerships define program advancement and ecosystem collaboration

Leading companies operating in the Canavan disease space demonstrate differentiated approaches across scientific focus, manufacturing strategy, and partnership models. Some developers emphasize platform depth in vector engineering and genome editing, investing heavily in preclinical validation and vector optimization to secure durable CNS expression and favorable safety profiles. Others prioritize translational agility by combining repurposed small molecules with supportive therapies to address symptom burden and extend therapeutic windows while gene-based programs mature. Across the board, partnerships between specialized biotech developers and larger pharmaceutical organizations are common, aligning deep scientific expertise with commercial infrastructure and payer engagement capabilities.

Contract development and manufacturing organizations have become indispensable partners, providing scalability and technical know-how for vector production and quality systems. Patient advocacy groups and clinical centers of excellence play a parallel role by contributing to natural history studies, facilitating trial recruitment, and shaping patient-reported outcome measures. Collectively, these stakeholders form an ecosystem in which collaboration, platform specialization, and operational excellence determine program momentum and long-term viability.

Actionable approaches for industry leaders to strengthen supply resilience, regulatory alignment, patient engagement and manufacturing scalability for rare disease programs

Industry leaders should pursue a set of actionable strategies to navigate the complex therapeutic development and commercialization pathway for Canavan disease. First, prioritizing supply chain resilience is essential: qualifying multiple suppliers, investing in regionally diversified manufacturing capacity, and developing robust inventory planning for critical raw materials will reduce program vulnerability. Second, aligning early with regulators on acceptable surrogate endpoints and adaptive trial designs can de-risk pivotal pathways and improve predictability for development timelines. Third, integrating patient advocacy groups into protocol co-design and natural history studies will increase trial relevance, accelerate recruitment, and strengthen real-world evidence capture.

In addition, companies should adopt modular manufacturing and platform-based approaches to maximize vector productivity and reduce per-batch variability, while pursuing cross-program learnings to shorten development cycles. Commercially, tailoring market access strategies to regional payer expectations and distribution infrastructures will improve adoption potential. Finally, investing in biomarker development and long-term follow-up frameworks will create clearer durability and safety narratives, which are critical for payer acceptance and for establishing sustainable reimbursement models. Implementing these actions in a coordinated manner will materially improve the probability of clinical and commercial success.

A transparent mixed-methods research approach combining literature synthesis, expert interviews, and rigorous triangulation to validate strategic conclusions and recommendations

This research employed a mixed-methods approach combining comprehensive secondary literature synthesis with primary qualitative interviews and rigorous cross-validation. Secondary inputs included peer-reviewed scientific literature, regulatory guidance documents, conference proceedings, and technical whitepapers to establish the scientific and regulatory context. Primary research consisted of structured interviews with clinicians specializing in leukodystrophies, manufacturing experts in viral vector production, regulatory affairs professionals, reimbursement specialists, and patient advocacy leaders to capture operational insights, prioritization criteria, and real-world constraints.

Findings were triangulated across data sources to minimize bias, and methodological rigor was maintained through standardized interview guides, anonymized respondent coding, and thematic analysis to distill convergent insights. Quality assurance included expert review by senior analysts with domain experience and iterative validation of conclusions against emerging public disclosures. Where appropriate, sensitivity checks and scenario mapping were used to test the robustness of strategic recommendations. The methodology emphasizes transparency, reproducibility, and a clear linkage between evidence and strategic conclusions.

Concluding perspectives on the imperative of operational resilience, strategic collaboration, and translational alignment to convert scientific advances into patient impact

Developing effective therapies for Canavan disease sits at the intersection of technical innovation, patient-centered trial design, and pragmatic operational execution. Scientific progress in vector design, genome editing, and supportive pharmacology has created multiple credible therapeutic avenues, but successful translation requires deliberate attention to manufacturing scale, regulatory strategy, and patient engagement. Short-term disruptions such as tariff-induced procurement challenges have underscored the need for resilient supply chains and regional manufacturing strategies, while advances in regulatory flexibility and trial design create opportunities to accelerate development without compromising evidence quality.

In summary, the ecosystem is poised for meaningful progress provided stakeholders align on robust operational frameworks, invest in manufacturing and biomarker infrastructure, and deepen collaboration with clinical and patient communities. These elements together can transform promising scientific advances into durable clinical options for patients living with Canavan disease.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Canavan Disease Therapeutics Market, by Therapy Type

  • 8.1. Enzyme Replacement Therapy
  • 8.2. Gene Therapy
    • 8.2.1. Aav Vector
    • 8.2.2. Lentiviral Vector
  • 8.3. Small Molecule Therapy
    • 8.3.1. Lithium
    • 8.3.2. N-Acetylcysteine

9. Canavan Disease Therapeutics Market, by Route Of Administration

  • 9.1. Intramuscular
  • 9.2. Intravenous
  • 9.3. Oral

10. Canavan Disease Therapeutics Market, by Therapy Line

  • 10.1. First-Line
  • 10.2. Second-Line

11. Canavan Disease Therapeutics Market, by Developer Type

  • 11.1. Biotech Companies
  • 11.2. Pharma Companies

12. Canavan Disease Therapeutics Market, by Technology

  • 12.1. Crispr-Cas9
  • 12.2. Talen
  • 12.3. Zfn

13. Canavan Disease Therapeutics Market, by Patient Age Group

  • 13.1. Adult Patients
  • 13.2. Pediatric Patients

14. Canavan Disease Therapeutics Market, by End User

  • 14.1. Clinics
  • 14.2. Homecare Settings
  • 14.3. Hospitals

15. Canavan Disease Therapeutics Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Canavan Disease Therapeutics Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Canavan Disease Therapeutics Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Canavan Disease Therapeutics Market

19. China Canavan Disease Therapeutics Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. Abeona Therapeutics Inc.
  • 20.6. Amgen, Inc.
  • 20.7. Anjarium Biosciences AG
  • 20.8. Astellas Pharma Inc.
  • 20.9. Biogen Inc.
  • 20.10. BridgeBio Pharma
  • 20.11. F. Hoffmann-La Roche Ltd.
  • 20.12. GlaxoSmithKline PLC
  • 20.13. Johnson & Johnson Services, Inc.
  • 20.14. Myrtelle, Inc.
  • 20.15. Novartis AG
  • 20.16. Orchard Therapeutics PLC
  • 20.17. Orphan Star Therapeutics LLC
  • 20.18. Pfizer, Inc.
  • 20.19. Sanofi SA
  • 20.20. Sio Gene Therapies Inc.
  • 20.21. Ultragenyx Pharmaceutical Inc.
  • 20.22. Voyager Therapeutics, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY AAV VECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY AAV VECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY AAV VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY LENTIVIRAL VECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY LENTIVIRAL VECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY LENTIVIRAL VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY LITHIUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY LITHIUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY LITHIUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY N-ACETYLCYSTEINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY N-ACETYLCYSTEINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY N-ACETYLCYSTEINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY FIRST-LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY FIRST-LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY FIRST-LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SECOND-LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SECOND-LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SECOND-LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY BIOTECH COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY BIOTECH COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY BIOTECH COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PHARMA COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PHARMA COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PHARMA COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY CRISPR-CAS9, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY CRISPR-CAS9, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY CRISPR-CAS9, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TALEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TALEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TALEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ZFN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ZFN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ZFN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. GCC CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. GCC CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. GCC CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 172. GCC CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 173. GCC CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 174. GCC CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 175. GCC CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. GCC CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 177. GCC CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. GCC CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. G7 CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 200. G7 CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. G7 CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 202. G7 CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 203. G7 CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 204. G7 CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 205. G7 CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. G7 CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 207. G7 CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 208. G7 CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. NATO CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. NATO CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. NATO CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 212. NATO CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 213. NATO CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 214. NATO CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 215. NATO CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. NATO CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 217. NATO CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 218. NATO CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)